CRISPR Therapeutics director awarded 13k stock options
CRISPR Therapeutics AG director Morrison Briggs received a grant of stock options for 13,000 common shares.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CRISPR Therapeutics AG director Morrison Briggs received a grant of stock options for 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036.
According to the vesting terms, the options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.
Insider Trade Summary
Grant/Award: 13,000 shares
Grant/Award
1 txn
Insider
Morrison Briggs
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 13,000 contracts (Direct)
Footnotes (1)
- F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Key Figures
Option grant size: 13,000 options
Exercise price: $51.84 per share
Underlying shares: 13,000 common shares
+3 more
6 metrics
Option grant size
13,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$51.84 per share
Exercise price for 13,000 underlying common shares
Underlying shares
13,000 common shares
Shares covered by the option grant
Expiration date
June 5, 2036
Option expiration
Vesting start
June 30, 2026
First monthly vesting installment
Final vesting trigger
Earlier of 1-year anniversary or 2027 Annual Meeting
Last installment vesting condition
Key Terms
Stock Option (Right to Buy), exercise price, vesting, Annual Meeting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 51.8400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"the options will vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting financial
"the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRISPR Therapeutics (CRSP) report for Morrison Briggs?
CRISPR Therapeutics reported that director Morrison Briggs received a grant of stock options for 13,000 common shares. These compensation-related options give him the right to buy shares at a fixed price if he continues serving the company through the vesting dates.
What is the exercise price of Morrison Briggs’ new CRSP stock options?
The granted stock options have an exercise price of $51.84 per share. This means Briggs can purchase up to 13,000 CRISPR Therapeutics common shares at $51.84, regardless of future market price, once the options vest and before they expire.
When do Morrison Briggs’ CRISPR Therapeutics stock options vest?
The options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting.
When do Morrison Briggs’ new CRSP stock options expire?
The stock options granted to Morrison Briggs expire on June 5, 2036. If he does not exercise vested options by that date, they will lapse and no longer allow him to purchase CRISPR Therapeutics common shares at the $51.84 exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
